BOSTON, Feb. 10, 2015
/PRNewswire/ -- PAREXEL International Corporation (NASDAQ:
PRXL), a leading global biopharmaceutical services provider, today
announced it has been recognized among top U.S. businesses in
Training magazine's annual "Training Top 125." PAREXEL
earned a place in the ranking this year for developing creative and
effective employee learning and development initiatives for their
global workforce.
"From traditional instructor-led settings to eLearning
environments, PAREXEL provides best-in-class learning products and
customized training programs to present employees with valuable
career and job skills development," said Albert Siu, Vice President, Learning and
Development, PAREXEL. "In the highly complex and regulated drug
development environment, having expertly trained employees around
the globe is an essential element to help our clients simplify
their journey toward bringing new drugs to market for
patients."
PAREXEL's comprehensive learning and training programs encompass
four primary learning domains including: company culture and
strategy; functional competencies; leadership development; and
professional development. The Company's standardized instructional
design model ensures training programs address the complexities of
global clinical trial requirements today, with each program
featuring a unique set of performance metrics to measure
operational and training effectiveness across the learning
disciplines.
"PAREXEL impressed us with its focus on delivering 'the right
training, to the right people, at the right time' to ensure its
employees are prepared to succeed in their jobs and careers," said
Lorri Freifeld, editor-in-chief,
Training magazine. "The competition was fierce this year, and
PAREXEL's global learning and development initiatives earned it
this well-deserved spot in our 2015 ranking."
In addition to training employees, PAREXEL is committed to
developing the future, global biopharmaceutical workforce with
courses specifically tailored to meet the growing talent needs of
the clinical development job market. Since 2001, the PAREXEL
Academy has designed and implemented a wide-range of learning and
performance programs tailored to enable clinical research
management practices for learners outside of PAREXEL. The PAREXEL
Academy has locations in the United
States, Europe, and
Asia.
For the last 15 years, Training magazine, the leading
business publication for learning and development professionals,
has issued its annual "Training Top 125," which ranks companies'
excellence in employer-sponsored training and development programs.
The ranking is based on myriad benchmarking statistics such as
total training budget; percentage of payroll; number of training
hours per employee program; goals, evaluation, measurement of
outcomes and impact, and workplace surveys; hours of training per
employee annually; and detailed formal programs.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc. provides
advanced technology solutions, including medical imaging, to
facilitate the clinical development process. Headquartered
near Boston, Massachusetts,
PAREXEL operates in 81 locations in 51 countries around the world,
and has approximately 16,530 employees. For more information
about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition of ClinIntel Limited, or enter into new
lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of foreign currency exchange rate fluctuations and
other international economic, political, and other
risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30,
2014 as filed with the Securities and Exchange Commission
on November 3, 2014, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1
781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
Video -
http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-NY28175-20150210-1.mp4
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-recognized-as-a-2015-training-top-125-by-training-magazine-300033470.html
SOURCE PAREXEL International Corporation